Last reviewed · How we verify
NCT05396066
Respiratory and Quadriceps Muscle Fatigability After an ICU Acquired Weakness
trial testing Muscle evaluation in ICU Acquired Weakness in 20 participants. Completed in 1 February 2024.
31 December 2023
Quick facts
| Lead sponsor | Groupe Hospitalier du Havre |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 15 June 2022 |
| Primary completion | 31 December 2023 |
| Estimated completion | 1 February 2024 |
| Sites | 1 location across France |
Drugs / interventions tested
- Muscle evaluation
Conditions studied
- ICU Acquired Weakness — all drugs for ICU Acquired Weakness →
Sponsor
Groupe Hospitalier du Havre
Who can join
Adults 18 to 80, any sex, with ICU Acquired Weakness. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Muscle dysfunction can be lead to poor outcomes moreover ICU muscle weakness recovery are not correctly described. The investigators aimed to assess the ability for quadriceps or respiratory muscles to repeat an effort at a maximal loading.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Respiratory and limb muscles' ability to repeatedly generate maximal isometric strength in patients with intensive care unit-acquired weakness: an observational study.
Machefert M, Prieur G, Aubry S, Combret Y, et al · · 2025 · PMID 40114068 · DOI 10.1186/s12871-025-03008-y
Verify or expand the search:
- PubMed search for NCT05396066
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for ICU Acquired Weakness
Currently open trials in the same condition.
- NCT07167121 — Predictive Validity of the Chelsea Critical Care Physical Assessment Tool (CPAx) for Regaining Autonomy Three Months Aft · recruiting
- NCT07162948 — ICU-Recover Box 2.0, Smart Technology for Home Monitoring of ICU Patients · NA · recruiting
- NCT06592144 — TESTO-TRIAL: Use of Testosterone in Critically Ill Patients · Phase 4 · active not recruiting
- NCT05919940 — Improved Muscle Metabolism by Combination of Muscle Activation and Protein Substitution ( IMEMPRO ) · NA · recruiting
- NCT05865314 — Optimised Nutritional Therapy and Early Physiotherapy in Long Term ICU Patients (NutriPhyT Trial) · NA · recruiting
Other Groupe Hospitalier du Havre trials
Trials by the same sponsor.
- NCT07371754 — Shear Wave Elastography of Intercostal Muscles for the Non-invasive Assessment of the Work of BreathinG · not yet recruiting
- NCT07492745 — Effect of Using a Reminder to Encourage Patients to be Active During Their Hospital Stay. · NA · recruiting
- NCT06994689 — Clinimetric Properties of Muscle Mass and Stiffness Measurements of the Quadriceps in Patients With COPD · recruiting
- NCT06249412 — The Importance of Positive Expiratory Pressure Associated With the In-exsufflator in ALS Patients · NA · recruiting
- NCT06772701 — Validation of the French Version of the Edinburgh Postnatal Depression Scale (EPDS) Postnatally in the Father · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05396066 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Groupe Hospitalier du Havre
- Last refreshed: 11 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05396066.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing